Drug Trial Radar · NCT04302870
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,150
Planned (sponsor's estimate)
Start
Feb 27, 2020
Primary completion
Dec 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- University of EdinburghAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University College, London; University of Warwick; NHS Lothian
- First posted
- Mar 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MND-SMART is investigating whether selected drugs can slow down the progression of motor neuron disease (MND) and improve survival. The study is 'multi-arm' meaning more than one treatment will be tested at the same time. The trial started with 3 arms; drug 1 (memantine), drug 2 (trazodone) and placebo (dummy drug). A third drug, amantadine, was added in April 2023. A fourth drug, tacrolimus, was added in March 2025 in Edinburgh and across all sites in April 2025. The first two drugs, memantine and trazodone, were removed from the trial in September 2023 due to lack of benefit. The trial currently has 4 recruiting arms; amantadine, liquid placebo (matched to amantadine), tacrolimus, and tablet placebo (matched to tacrolimus). This allows the evaluation of each drug versus placebo. Participants will be randomly allocated between the treatment arms they are eligible for. Medicines being tested are already approved for use in other conditions. MND-SMART has an 'adaptive' design. This means medicines being studied can change according to emerging results. Treatments shown to be ineffective can be dropped and new drugs can be added over the duration of the study. This will allow many treatments, over time, to be efficiently and definitively evaluated. The medicines being tested have been selected following a rigorous process involving a systematic, unbiased, and comprehensive review of past clinical trials data, as well as information from pre-clinical research (studies in laboratories), for MND and other related neurodegenerative disorders. Drugs have been ranked for inclusion in MND-SMART by a group of independent MND experts according to set criteria. These include consideration of how the drugs work, their safety profiles, and the quality of previous studies. New drugs will be selected for investigation in MND-SMART based on continuous review of constantly updated scientific evidence as well as findings from state-of-the-art human stem cell based drug discovery platforms. These can be added by substantial amendment to the protocol.
Conditions
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Memantine Hydrochloride Oral SolutionDrug
Memantine hydrocholoride taken once daily
Trazodone Hydrochloride oral solutionDrug
Trazodone Hydrochloride taken once daily
Placebo oral solutionDrug
Placebo taken once daily
Amantadine Hydrochloride Oral SolutionDrug
Amantadine Hydrochloride taken once daily
Tacrolimus 1Mg CapDrug
Tacrolimus 1Mg overencapsulated tablet taken once daily
Placebo capsuleDrug
Placebo taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in decline of ALS-FRS(R) over 18monthsTime frame: 18 months
- SurvivalTime frame: 18 months
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Aberdeen Royal Infirmary
Aberdeen, United Kingdom · Recruiting
University Hospitals of Birmingham NHS Foundation Trust
Birmingham, United Kingdom · Recruiting
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom · Recruiting
West Suffolk NHS Foundation Trust
Bury St Edmunds, United Kingdom · Recruiting
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom · Recruiting
Cardiff and Vale University Local Health Board
Cardiff, United Kingdom · Recruiting
Clinical Research Centre , Ninewells Hospital
Dundee, United Kingdom · Recruiting
Anne Rowling Regenerative Neurology Clinic
Edinburgh, United Kingdom · Recruiting
Royal Devon and Exeter Hospital
Exeter, United Kingdom · Recruiting
Queen Elizabeth University Hospital Clinical Research Facility
Glasgow, United Kingdom · Recruiting
NHS Highland Clinical Research Facility, Raigmore Hospital
Inverness, United Kingdom · Recruiting
East Suffolk and North Essex NHS Foundation Trust
Ipswich, United Kingdom · Recruiting
Royal London Hospital
London, United Kingdom · Recruiting
St George's University Hospitals NHS Foundation Trust
London, United Kingdom · Recruiting
King's College Hospital NHS Foundation Trust
London, United Kingdom · Recruiting
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom · Recruiting
Norfolk and Norwich University Hospitals NHS Foundation Trust
Norwich, United Kingdom · Recruiting
University Hospitals of Dorset NHS Trust
Poole, United Kingdom · Recruiting
Clinical Research Facility Salford Royal NHS Foundation Trust
Salford, United Kingdom · Recruiting
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom · Recruiting
Clinical Research Facility University Hospital Southampton
Southampton, United Kingdom · Recruiting
Southern Health and Social Care Trust, Craigavon Area Hospital
Portadown, County Armagh, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.